

Reference.....

BWH/3

86^A

Dr K Fowler

FVIII CONCENTRATE WITH REDUCED HEPATITIS RISK

Are you able to let me know whether any FVIII concentrate claiming reduced risk of hepatitis transmission has been submitted for product licensing?

I believe Travenol plans to hold a symposium in January to 'launch' such a product (presumably for clinical trials) in the UK.

DIANA WALFORD

MED SEB

Room 1025A HAN H

Ext **GRO-C**

22 December 1982

cc Mr Godfrey ✓

Mr Green

There are several implications in this. First, clinicians may insist on using the "hepatitis free" product at great cost, and turn away from the BPL product. Second, even if BPL were to 'buy in' the technology on an agency royalty basis, the technique involved in arriving at the hepatitis risk reduced FVIII reduces yield considerably. Goodness knows what size factory we'd need!

BPL are aware of developments and staged a seminar for RTDs, Haem. Centre Directors etc earlier this month. They are of course doing the same work on reducing the hepatitis risk.

CODE 18-78

GRO-C **GRO-C**

24/12/82